Santersus raises CHF 750,000 in family & friends round Verified listing

Tuesday, September 1, 2020 @ 12:00 am

Santersus AG (Switzerland), a privately held innovative plasmapheresis start-up company, has closed a CHF 750 thousand post-seed funding round. “The Company intends to use the net proceeds for the clinical and regulatory development,” said Scott Maguire, the chairman of Santersus AG.

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

Helsinn Healthcare & InVirtuoLabs: Collaboration in AI-driven drug discovery

Helsinn Healthcare SA (Helsinn), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, and In Virtuo Laboratories SA (InVirtuoLabs), a Lugano-based drug discovery company specializing in AI-powered generative chemistry, today announced a strategic collaboration to discover and develop novel small-molecule therapeutics.
February 25, 2026

Medistri becomes member of Swiss Medtech

Medistri, a provider of contract sterilization, laboratory, packaging validation, manufacturing, logistics, and consulting services for the healthcare industry, has become a member of Swiss Medtech, the association representing the Swiss MedTech sector.
February 24, 2026

Biolizard: Alexander Scheer joins leadership team to advance AI-driven solutions

BioLizard has appointed Dr. Alexander Scheer as Chief Scientific Officer, adding 25+ years of translational R&D leadership across biotech and pharma in November 2025. He will help scale BioLizard’s multi-omics and AI-driven strategy, strengthening work in biomarkers, precision medicine, and therapeutic innovation.
February 24, 2026

LubioScience and Mabtech strengthen immunoassay access

LubioScience and Mabtech have entered into a strategic partnership to strengthen the availability of high-quality immunoassay solutions for research and diagnostics customers in Switzerland. The collaboration combines Mabtech’s internationally recognised ELISA, EYRAplex, ELISpot and FluoroSpot technologies with LubioScience’s established distribution network and local scientific support, aimin
February 23, 2026

Umlaut.bio: Prestigious funding by BaseLaunch and strengthing scientific advisory board

BaseLaunch selects Umlaut.bio for support thereby raising the pre-seed funding to a total of ~EUR 3m Prof. Dr. Oliver Distler, Universitätspital Zurich, joins Umlaut.bio’s SAB catalyzing the development of the systemic sclerosis franchise Prof. Dr. Tsutomu Suzuki, University Tokio, completes the SAB, underpinning the worldwide leadership in tRNA science
February 19, 2026